Seeking Alpha

Human Genome (HGSI +0.6%) should still see a higher bid, says Baird, noting they "remain...

Human Genome (HGSI +0.6%) should still see a higher bid, says Baird, noting they "remain confident" that a higher bid will emerge despite Glaxo's (GSK +0.3%) indication it will suspend the tender offer while the company's poison pill is in effect. The firm met with management and said their calculations point to a bid closer to $20.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)